Teva Pharmaceuticals USA Inc.
Россия
  • Россия
  • Украина

Teva Pharmaceuticals USA Inc.

Contact Details

1090 Horsham Rd, North Wales, Pennsylvania, USA 19454-1505
97239267267

1090 Horsham Rd, North Wales, Pennsylvania, USA 19454-1505

Contact Information

Phone
97239267267
Fax(215) 591-8600
Website 1http://www.tevausa.com
FacebookFacebook
LinkedInLinkedIn
Twitter@tevapharm

Products

Drug NameCondition
Phenylephrine HCl InjectionCHF and arrhythmias
Phenylephrine HCl InjectionHypotension
TEV-TROPINPituitary disorders

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
Chief Scientific Officer and Divisional President
Geographical CEO and Geographical President
Divisional Vice President
Geographical CEO and Geographical President
CEO and President2005
Vice Chairman and Director
Director
Director, President and CEO
Divisional Vice President
Divisional Vice President
Other Executive Officer
Director
Director
Director
Director

Government Contracts

Largest Contracts

AgencyProduct or ServiceSigned DateObligation Amount
Department of Veterans AffairsDrugs and BiologicalsJanuary 03, 2007$12.1 million
Department of the ArmyChemical and Pharmaceutical Products Manufacturing Machinery, Medical - Basic ResearchAugust 22, 2005$7.46 million
Defense Logistics AgencyDrugs and Biologicals, Replenishable Field Medical Sets, Kits and OutfitsFebruary 01, 2002$1.43 million
Department of Veterans AffairsChemical and Pharmaceutical Products Manufacturing Machinery, Drugs and Biologicals, Medical and Surgical Instruments, Equipment and SuppliesMarch 18, 2008$441,393.93
Department of the ArmyProfessional ServicesJune 17, 2004$260,700

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing
  • Medicinal and Botanical Manufacturing
  • Drugs and Druggists` Sundries Merchant Wholesalers

SIC Industries

  • Pharmaceutical Preparations
  • Medicinals And Botanicals
  • Pharmaceuticals

Company Size

Sales Volume$19.7 billion
Employees43,000

Ownership

Ticker SymbolTEVA
ExchangeNew York Stock Exchange (NYSE)
Type of EntityFor Profit Organization
Type of OwnershipNot Tax Exempt Corporate Entity
Other Categorizations
  • Foreign Owned and Located
  • Manufacturer of Goods
Year Founded1985

Stocks

Previous Close55.92
Open55.88
Bid55.55 x 100
Ask55.58 x 700
Day`s Range55.50 - 56.16
52-Week Range53.5 - 72
Average Volume (1M)5,837,260
Forward P/E10.26x
Trailing P/E10.39x
Beta0.77x
Market Cap.$51,092.4 Million
Dividend & Yield1.16 (2.05%)

Corporate Venture Capital Investments

Companies Abbott Laboratories Has Invested In

CompanyCurrent StageIndustryEarliest InvestmentDate
Cocrystal Merger Sub Inc.Out of BusinessBiotechnologyVenture Equity ($7,500,000)09/15/11
Vaccinex LPEarlyBiotechnologySeries B ($25,000,000)02/26/08
MediWoundExited (IPO)BiotechnologyVenture Equity ($30,000,000)06/21/07
TransPharma MedicalOut of BusinessPharmaceuticalSeries C ($18,000,000)07/24/06

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue4,881,0004,823,0004,966,0004,982,000
Cost of Revenue2,034,0002,052,0002,064,0002,146,000
Gross Profit2,847,0002,771,0002,902,0002,836,000
Research Development446,000361,000386,000332,000
Selling General and Administrative1,207,0001,096,0001,185,0001,229,000
Depreciation and Amortization----
Other Operating Expenses100,000(80,000)384,000227,000
Total Operating Expenses3,787,0003,429,0004,019,0003,934,000
Other Income/Expenses Net----
Earnings Before Interest and Taxes1,094,0001,394,000947,0001,048,000
Interest Expense----
Income Before Tax861,000313,000621,000557,000
Income Tax Expense249,000193,00088,000104,000
Minority Interest----
Net Income from Continuing Ops498,000116,000539,000444,000
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items2,000(13,000)-2,000
Net Income500,000103,000539,000446,000
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares485,000103,000539,000446,000